169 related articles for article (PubMed ID: 12577236)
1. Preclinical studies on the radioprotective efficacy and pharmacokinetics of subcutaneously administered amifostine.
Cassatt DR; Fazenbaker CA; Kifle G; Bachy CM
Semin Oncol; 2002 Dec; 29(6 Suppl 19):2-8. PubMed ID: 12577236
[TBL] [Abstract][Full Text] [Related]
2. Effects of dose and schedule on the efficacy of ethyol: preclinical studies.
Cassatt DR; Fazenbaker CA; Kifle G; Bachy CM
Semin Oncol; 2003 Dec; 30(6 Suppl 18):31-9. PubMed ID: 14727238
[TBL] [Abstract][Full Text] [Related]
3. Tissue levels of WR-1065, the active metabolite of amifostine (Ethyol), are equivalent following intravenous or subcutaneous administration in cynomolgus monkeys.
Bachy CM; Fazenbaker CA; Kifle G; McCarthy MP; Cassatt DR
Oncology; 2004; 67(3-4):187-93. PubMed ID: 15557777
[TBL] [Abstract][Full Text] [Related]
4. Subcutaneous administration of amifostine (ethyol) is equivalent to intravenous administration in a rat mucositis model.
Cassatt DR; Fazenbaker CA; Kifle G; Bachy CM
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):794-802. PubMed ID: 14529786
[TBL] [Abstract][Full Text] [Related]
5. Preclinical modeling of improved amifostine (Ethyol) use in radiation therapy.
Cassatt DR; Fazenbaker CA; Bachy CM; Hanson MS
Semin Radiat Oncol; 2002 Jan; 12(1 Suppl 1):97-102. PubMed ID: 11917293
[TBL] [Abstract][Full Text] [Related]
6. Novel Formulation Strategy to Improve the Feasibility of Amifostine Administration.
Ranganathan K; Simon E; Lynn J; Snider A; Zhang Y; Nelson N; Donneys A; Rodriguez J; Buchman L; Reyna D; Lipka E; Buchman SR
Pharm Res; 2018 Mar; 35(5):99. PubMed ID: 29556791
[TBL] [Abstract][Full Text] [Related]
7. Amifostine (ETHYOL) protects rats from mucositis resulting from fractionated or hyperfractionated radiation exposure.
Cassatt DR; Fazenbaker CA; Bachy CM; Kifle G; McCarthy MP
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):901-7. PubMed ID: 15708273
[TBL] [Abstract][Full Text] [Related]
8. Feasibility study of the pharmacology of local application of amifostine (WR-2721) to the buccal mucosa in guinea pigs.
Li C; Wang S; Huang T; Chen N; Ou M
Pharmacology; 2013; 91(5-6):281-6. PubMed ID: 23736649
[TBL] [Abstract][Full Text] [Related]
9. New dosing regimens for amifostine: a pilot study to compare the relative bioavailability of oral and subcutaneous administration with intravenous infusion.
Bonner HS; Shaw LM
J Clin Pharmacol; 2002 Feb; 42(2):166-74. PubMed ID: 11831539
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of amifostine and its metabolites in the plasma and ascites of a cancer patient.
Korst AE; Gall HE; Vermorken JB; van der Vijgh WJ
Cancer Chemother Pharmacol; 1996; 39(1-2):162-6. PubMed ID: 8995515
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic profile of amifostine.
Shaw LM; Bonner H; Lieberman R
Semin Oncol; 1996 Aug; 23(4 Suppl 8):18-22. PubMed ID: 8783662
[TBL] [Abstract][Full Text] [Related]
12. A new orally active, aminothiol radioprotector-free of nausea and hypotension side effects at its highest radioprotective doses.
Soref CM; Hacker TA; Fahl WE
Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):e701-7. PubMed ID: 22330992
[TBL] [Abstract][Full Text] [Related]
13. Subcutaneous administration of amifostine during fractionated radiotherapy: a randomized phase II study.
Koukourakis MI; Kyrias G; Kakolyris S; Kouroussis C; Frangiadaki C; Giatromanolaki A; Retalis G; Georgoulias V
J Clin Oncol; 2000 Jun; 18(11):2226-33. PubMed ID: 10829042
[TBL] [Abstract][Full Text] [Related]
14. A phase I clinical and pharmacology study using amifostine as a radioprotector in dose-escalated whole liver radiation therapy.
Feng M; Smith DE; Normolle DP; Knol JA; Pan CC; Ben-Josef E; Lu Z; Feng MR; Chen J; Ensminger W; Lawrence TS
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1441-7. PubMed ID: 22440042
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of amifostine: effects of dose and method of administration.
Shaw LM; Bonner HS; Schuchter L; Schiller J; Lieberman R
Semin Oncol; 1999 Apr; 26(2 Suppl 7):34-6. PubMed ID: 10348258
[TBL] [Abstract][Full Text] [Related]
16. Preliminary data of the GORTEC 2000-02 phase III trial comparing intravenous and subcutaneous administration of amifostine for head and neck tumors treated by external radiotherapy.
Bardet E; Martin L; Calais G; Tuchais C; Bourhis J; Rhein B; Feham N; Alphonsi M
Semin Oncol; 2002 Dec; 29(6 Suppl 19):57-60. PubMed ID: 12577246
[TBL] [Abstract][Full Text] [Related]
17. Disposition of WR-1065 in the liver of tumor-bearing rats following regional vs systemic administration of amifostine.
Levi M; DeRemer SJ; Dou C; Ensminger WD; Smith DE
Biopharm Drug Dispos; 2004 Jan; 25(1):27-35. PubMed ID: 14716750
[TBL] [Abstract][Full Text] [Related]
18. CCM-AMI, a Polyethylene Glycol Micelle with Amifostine, as an Acute Radiation Syndrome Protectant in C57BL/6 Mice.
Chen CH; Kuo ML; Wang JL; Liao WC; Chang LC; Chan LP; Lin J
Health Phys; 2015 Sep; 109(3):242-8. PubMed ID: 26222219
[TBL] [Abstract][Full Text] [Related]
19. Selective radioprotection of hepatocytes by systemic and portal vein infusions of amifostine in a rat liver tumor model.
Symon Z; Levi M; Ensminger WD; Smith DE; Lawrence TS
Int J Radiat Oncol Biol Phys; 2001 Jun; 50(2):473-8. PubMed ID: 11380236
[TBL] [Abstract][Full Text] [Related]
20. Amelioration of early radiation effects in oral mucosa (mouse) by intravenous or subcutaneous administration of amifostine.
Fleischer G; Dörr W
Strahlenther Onkol; 2006 Oct; 182(10):567-75. PubMed ID: 17013569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]